Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy

Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy

Background: Phase 3 studies of immune checkpoint inhibitors have not shown a survival benefit in prostate cancer, but some patients have a profound anticancer response.Patients and Methods: We evaluated the efficacy of the CTLA-4 targeted agent, ipilimumab, in metastatic prostate cancer patients who...

Full description

Bibliographic Details
Main Authors: Julie N. Graff, Mark N. Stein, Rishi Surana, Luai Al Rabadi, Eric Liu, Lawrence Fong, Shawna Bailey, Emile Latour, Timothy A. Newby, Amy E. Moran, Tomasz M. Beer
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Oncology
Subjects:
prostate cancer
immunotherapy
CTLA-4
metastatic
checkpoint inhibitor
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01381/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01381/full

Similar Items